logo for Neuren Pharmaceuticals

Neuren Pharmaceuticals

Business Services · Australia · 269 Employees

View Company Info for Free

About

Headquarters

697 Burke Rd Ste 201, Camberwell, Victoria, 312...

Revenue

$52.6 Million

Stock Symbol

NEU

Industry

Business Services General Business Services

Who is Neuren Pharmaceuticals

About Neuren Neuren is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood, none of which have any approved medicines. The lead compound, trofinetide, achieved positive results in a Phase 3 clinical trial for Rett syndrome and has also completed a Phase 2 clinical trial in Fragile X syndrome. Both programs have Fast Track designation from the US Food and Drug Administration (FDA). Neuren has granted an exclusive licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America. Neuren is preparing to initiate Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan- McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. Recognising the urgent unmet need, all six programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.Read more

Neuren Pharmaceuticals's Social MediaPopular SearchesNeuren Pharmaceuticals LtdNeuren PharmaceuticalsNeuren Pharmaceuticals IncNeuren Pharmaceuticals( ASXPharmaceuticals LtdSIC Code 28,283NAICS Code 32,325Ticker ASX: NEUShow more

Neuren Pharmaceuticals Org Chart

Jon Pilcher

Chief Executive Officer

PhoneEmail
Lauren Frazer

Chief Financial Officer

PhoneEmail
Liza Squires

Chief Medical Officer

PhoneEmail

PhoneEmail

Similar Companies to Neuren Pharmaceuticals

  1. 329
    <$5M

    1

  2. 1,558
    $317.7M

    2

  3. 140
    $16M

    3

  4. 35
    <$5M

    4

  5. 304
    $63.4M

    5

  6. 69
    <$5M

    6

See more similar companies

Neuren Pharmaceuticals Tech Stack

A closer look at the technologies used by Neuren Pharmaceuticals

Top Companies in Australia

Top 10 companies in Australia by revenue

Top 10 companies in Australia by number of employees

Top 10 companies in Australia by total funding amount

See top companies

Neuren Pharmaceuticals News & Media

Read more news

Frequently Asked Questions regarding Neuren Pharmaceuticals

Where is Neuren Pharmaceuticals located?
Neuren Pharmaceuticals's headquarters are located at 697 Burke Rd Ste 201, Camberwell, Victoria, 3124, Australia
What is Neuren Pharmaceuticals's stock symbol?
Neuren Pharmaceuticals's stock symbol is NEU
What is Neuren Pharmaceuticals's official website?
Neuren Pharmaceuticals's official website is www.neurenpharma.com
What is Neuren Pharmaceuticals's Revenue?
Neuren Pharmaceuticals's revenue is $52.6 Million
What is Neuren Pharmaceuticals's SIC code?
Neuren Pharmaceuticals's SIC: 28,283
What is Neuren Pharmaceuticals's NAICS code?
Neuren Pharmaceuticals's NAICS: 32,325
How many employees does Neuren Pharmaceuticals have?
Neuren Pharmaceuticals has 269 employees
What industry does Neuren Pharmaceuticals belong to?
Neuren Pharmaceuticals is in the industry of: Business Services General, Business Services
What is Neuren Pharmaceuticals competition?
Neuren Pharmaceuticals top competitors include: Antengene Corp, Novotech Ltd, Nucleus Network Pty Ltd, Immutep Ltd
What technology does Neuren Pharmaceuticals use?
Some of the popular technologies that Neuren Pharmaceuticals uses are: WPForms, Bullhorn, Google Global Site Tag, reCAPTCHA
Who is the CEO of Neuren Pharmaceuticals?
Neuren Pharmaceuticals's CEO is Jon Pilcher
Who is the CFO of Neuren Pharmaceuticals?
Neuren Pharmaceuticals's CFO is Lauren Frazer
What does Neuren Pharmaceuticals do?

About Neuren Neuren is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood, none of which have any approved medicines. The lead compound, trofinetide, achieved positive results in a Phase 3 clinical trial for Rett syndrome and has also completed a Phase 2 clinical trial in Fragile X synd... rome. Both programs have Fast Track designation from the US Food and Drug Administration (FDA). Neuren has granted an exclusive licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America. Neuren is preparing to initiate Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan- McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. Recognising the urgent unmet need, all six programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.Read More

What are Neuren Pharmaceuticals social media links?
Neuren Pharmaceuticals Linkedin page
Is Neuren Pharmaceuticals a public company?
Yes, Neuren Pharmaceuticals is a public company and is traded under the symbol NEU
See more information about Neuren Pharmaceuticals

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.